Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNL012
MIFTS: 57

Penile Cancer

Categories: Cancer diseases, Reproductive diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Penile Cancer

About this section

MalaCards integrated aliases for Penile Cancer:

Name: Penile Cancer 12 37 15
Penis Carcinoma 12 15 73
Penile Neoplasms 44 73
Penile Neoplasm 12 15
Malignant Neoplasm of Body of Penis 12
Malignant Neoplasm of Penis 73
Malignant Penile Tumor 12
Carcinoma of Penis 12
Neoplasm of Penis 12
Penile Carcinoma 12
Penile Tumor 12
Penile Ca 12
Ca Penis 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Penile Cancer

About this section
Disease Ontology : 12 A penile cancer that is located in the skin or tissues of the penis.

MalaCards based summary : Penile Cancer, also known as penis carcinoma, is related to anogenital venereal wart and papilloma. An important gene associated with Penile Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Viral carcinogenesis and PI3K-Akt signaling pathway. The drugs Fentanyl and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the skin or tissues of the penis, lymph node and skin, and related phenotypes are cardiovascular system and integument

Wikipedia : 76 Penile cancer is a malignant growth found on the skin or in the tissues of the penis. Around 95% of... more...

Sources

Related Diseases for Penile Cancer

About this section

Diseases in the Penile Cancer family:

Penile Cancer, Adult

Diseases related to Penile Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 anogenital venereal wart 30.5 CDKN2A TP53
2 papilloma 30.2 CCND1 CDKN2A TP53
3 squamous cell carcinoma 29.4 CCND1 CDKN2A EGFR HRAS TP53
4 cervical cancer 29.3 CCND1 CDKN2A HRAS TP53
5 adenocarcinoma 28.9 CCND1 CDKN2A EGFR HRAS TP53
6 bladder cancer 28.8 CCND1 CDKN2A EGFR HRAS TP53
7 penile cancer, adult 12.1
8 penis carcinoma in situ 12.1
9 penile cancer, childhood 12.0
10 penis squamous cell carcinoma 11.5
11 penis verrucous carcinoma 11.0
12 penis basaloid carcinoma 11.0
13 penis papillary carcinoma 11.0
14 malignant peritoneal mesothelioma 10.8 CDKN2A EGFR
15 brain stem astrocytic neoplasm 10.8 CDKN2A TP53
16 anaplastic oligodendroglioma 10.8 CDKN2A EGFR
17 brain ependymoma 10.8 EGFR TP53
18 breast papillomatosis 10.8 CCND1 CDKN2A
19 keratinizing squamous cell carcinoma 10.8 CDKN2A TP53
20 bowenoid papulosis 10.8 CCND1 CDKN2A
21 bladder carcinoma in situ 10.7 CDKN2A TP53
22 bartholin's gland benign neoplasm 10.7 CDKN2A TP53
23 vulva squamous cell carcinoma 10.7 CDKN2A TP53
24 skin carcinoma in situ 10.7 CCND1 CDKN2A
25 thyroid lymphoma 10.7 CDKN2A TP53
26 endometrial squamous cell carcinoma 10.7 CCND1 CDKN2A
27 bone squamous cell carcinoma 10.7 CDKN2A TP53
28 scrotal carcinoma 10.7 CDKN2A TP53
29 anal squamous cell carcinoma 10.7 CDKN2A TP53
30 glycogen-rich clear cell breast carcinoma 10.7 CDKN2A TP53
31 cervical adenosquamous carcinoma 10.7 CDKN2A EGFR
32 gastric adenosquamous carcinoma 10.7 CDKN2A TP53
33 breast squamous cell carcinoma 10.7 EGFR TP53
34 megaesophagus 10.7 CDKN2A TP53
35 non-proliferative fibrocystic change of the breast 10.7 CCND1 TP53
36 gallbladder adenoma 10.7 CDKN2A HRAS
37 ischemic fasciitis 10.7 CCND1 CDKN2A
38 cervix uteri carcinoma in situ 10.7 CDKN2A TP53
39 schneiderian carcinoma 10.7 CDKN2A TP53
40 synchronous bilateral breast carcinoma 10.7 CCND1 TP53
41 paronychia 10.7 EGFR HRAS
42 microglandular adenosis 10.7 EGFR TP53
43 melanomatosis 10.7 CDKN2A HRAS
44 pulmonary blastoma 10.6 EGFR TP53
45 dedifferentiated liposarcoma 10.6 CDKN2A TP53
46 suppressor of tumorigenicity 3 10.6 CDKN2A TP53
47 pleomorphic carcinoma 10.6 EGFR TP53
48 cll/sll 10.6 CCND1 TP53
49 gliomatosis cerebri 10.6 EGFR TP53
50 endocervical adenocarcinoma 10.6 CDKN2A TP53

Graphical network of the top 20 diseases related to Penile Cancer:



Diseases related to Penile Cancer
Sources

Symptoms & Phenotypes for Penile Cancer

About this section

MGI Mouse Phenotypes related to Penile Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 HRAS SCN10A TP53 APP CCND1 CDKN2A
2 integument MP:0010771 9.8 HRAS SCN10A TP53 APP CCND1 CDKN2A
3 neoplasm MP:0002006 9.55 EGFR HRAS TP53 CCND1 CDKN2A
4 no phenotypic analysis MP:0003012 9.43 HRAS SCN10A TP53 APP CDKN2A EGFR
5 respiratory system MP:0005388 9.1 EGFR HRAS SCN10A TP53 CCND1 CDKN2A
Sources

Drugs & Therapeutics for Penile Cancer

About this section

Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
6 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
7 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
8 Adjuvants, Anesthesia Phase 3
9 Analgesics Phase 3,Phase 2
10 Analgesics, Opioid Phase 3
11 Anesthetics Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics, Intravenous Phase 3
14 Central Nervous System Depressants Phase 3,Phase 2
15 Narcotics Phase 3
16 Peripheral Nervous System Agents Phase 3,Phase 2
17 Albumin-Bound Paclitaxel Phase 3,Phase 2
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 3,Phase 2
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
22
Isophosphamide mustard Phase 3,Phase 2 0
23 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
24
Indinavir Approved Phase 2 150378-17-9 5362440
25
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
26
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
27
Isotretinoin Approved Phase 2 4759-48-2 5538 5282379
28
Aldesleukin Approved Phase 1, Phase 2,Phase 2 85898-30-2, 110942-02-4
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 50-18-0, 6055-19-2 2907
30
Fludarabine Approved Phase 1, Phase 2,Phase 2 21679-14-1, 75607-67-9 30751
31
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 32326 21704
32
Pembrolizumab Approved Phase 2 1374853-91-4
33
Daratumumab Approved Phase 1, Phase 2 945721-28-8
34
nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
35
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
36
Vinblastine Approved Phase 2 865-21-4 13342 241903
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
39
Camptothecin Experimental Phase 2 7689-03-4
40 Anti-HIV Agents Phase 2,Phase 1
41 Anti-Infective Agents Phase 2,Phase 1
42 Anti-Retroviral Agents Phase 2,Phase 1
43 Antiviral Agents Phase 2,Phase 1
44 Cytochrome P-450 CYP3A Inhibitors Phase 2
45 Cytochrome P-450 Enzyme Inhibitors Phase 2
46 HIV Protease Inhibitors Phase 2
47
protease inhibitors Phase 2
48 interferons Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 2
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Recruiting NCT02305654 Phase 3 Paclitaxel;Ifosfamide;Cisplatin
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
4 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
5 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
6 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
7 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
8 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
9 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
10 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
11 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) Recruiting NCT02817958 Phase 2 Chemotherapie TIP
12 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2 Dacomitinib
13 Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Recruiting NCT02837042 Phase 2 Pembrolizumab
14 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
15 HPV Anti-CD40 RNA Vaccine Recruiting NCT03418480 Phase 1, Phase 2 HPV vaccine
16 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
17 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
18 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
19 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
20 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
21 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2 Vinflunine
22 A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy Not yet recruiting NCT03391479 Phase 2 Avelumab
23 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2 docetaxel
24 Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) Terminated NCT02279576 Phase 2 Pazopanib;Paclitaxel
25 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
26 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
27 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
28 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
29 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
30 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
31 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
32 Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers Completed NCT02526316 Phase 1
33 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
34 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
35 Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] Unknown status NCT02104063
36 Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Completed NCT01526486 Not Applicable
37 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053 Gabapentin prescriptions
38 Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents Completed NCT02236273 Not Applicable
39 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
40 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
41 HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men Recruiting NCT02897427 Not Applicable
42 Laser Fluorescence in Cancer Surgical Treatment Recruiting NCT03021200 Not Applicable
43 Development of Diagnostics and Treatment of Urological Cancers Recruiting NCT02994758 Not Applicable
44 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
45 Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy Active, not recruiting NCT00955929 Not Applicable Placebo QHS and sildenafil and questionnaires;Sildenafil and questionnaire;Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
46 Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV) Not yet recruiting NCT03267251 Not Applicable
47 Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Not yet recruiting NCT03346915 Not Applicable

Search NIH Clinical Center for Penile Cancer

Cochrane evidence based reviews: penile neoplasms

Sources

Genetic Tests for Penile Cancer

About this section
Sources

Anatomical Context for Penile Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Penile Cancer:

19
The Skin Or Tissues Of The Penis

MalaCards organs/tissues related to Penile Cancer:

41
Lymph Node, Skin, Brain, Liver, T Cells, Prostate, Neutrophil
Sources

Publications for Penile Cancer

About this section

Articles related to Penile Cancer:

(show top 50) (show all 448)
# Title Authors Year
1
Penile cancer in MaranhALo, Northeast Brazil: the highest incidence globally? ( 29843769 )
2018
2
The case for nonsurgical therapy of nonmetastatic penile cancer. ( 29950592 )
2018
3
Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway. ( 29662627 )
2018
4
PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer. ( 29902261 )
2018
5
Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. ( 29880898 )
2018
6
Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. ( 29433986 )
2018
7
The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. ( 29589134 )
2018
8
Penile cancer: Providing patient support. ( 29517510 )
2018
9
Predictors of lymph node status in penile cancer: High-quality administrative datasets give us insight into what's happening in our own backyard. ( 29681264 )
2018
10
Penile cancer: Providing patient support. ( 29561368 )
2018
11
Lymphangioma Circumscriptum Post Radiotherapy for Penile Cancer Treated with COa88 Laser. ( 29782301 )
2018
12
Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. ( 29703686 )
2018
13
Prognostic factors in patients with penile cancer after surgical management. ( 29299663 )
2018
14
Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. ( 29197968 )
2018
15
Neo-glans reconstruction for penile cancer: Description of the primary technique using autologous testicular tunica vaginalis graft. ( 29892486 )
2018
16
Comparative Study of Video Endoscopic Inguinal Lymphadenectomy Through a Hypogastric vs Leg Subcutaneous Approach for Penile Cancer. ( 29256632 )
2018
17
Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. ( 29730019 )
2018
18
Increased Risk of Penile Cancer among Men Working in Agriculture: Some Methodological Issues ( 29801393 )
2018
19
[18F]FDG PET/CT for assessing inguinal lymph nodes in patients with penile cancer - correlation with histopathology after inguinal lymphadenectomy. ( 29536497 )
2018
20
Penile-sparing modalities in the management of low-stage penile cancer. ( 29416267 )
2018
21
Penile cancer sparing surgery: The balance between oncological cure and functional preservation. ( 29306557 )
2018
22
The analysis of human papillomavirus DNA in penile cancer tissue by <i>in situ</i> hybridization. ( 29731917 )
2018
23
Management of Penile Cancer. ( 29942204 )
2018
24
Increased Risk of Penile Cancer among Men Working in Agriculture ( 29374407 )
2018
25
A Comparative study of two types of organ-sparing surgeries for early stage penile cancer: Wide local excision vs partial penectomy. ( 29656798 )
2018
26
Re: Sarah R. Ottenhof, Andrew Leone, Rosa S. Djajadiningrat, et al. Surgical and Oncological Outcomes in Patients After Vascularized Flap Reconstruction for Locoregionally Advanced Penile Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.02.002. ( 29674120 )
2018
27
Current Management Strategy for Penile Cancer and Future Directions. ( 28664471 )
2017
28
The role of PET/CT imaging in penile cancer. ( 29184780 )
2017
29
Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. ( 28499559 )
2017
30
Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine. ( 28411892 )
2017
31
Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer. ( 28118628 )
2017
32
Comparison of efficacy between brachytherapy and penectomy in patients with penile cancer: a meta-analysis. ( 29245993 )
2017
33
Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. ( 28900475 )
2017
34
Immunotherapy for penile cancer. ( 28883996 )
2017
35
Validation of predictors for lymph node status in penile cancer: Results from a population-based cohort. ( 29319487 )
2017
36
Surveillance strategies in the management of penile cancer. ( 29184784 )
2017
37
Surgical treatment of advanced penile cancer. ( 28493019 )
2017
38
National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012). ( 28866244 )
2017
39
Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive. ( 29184781 )
2017
40
Proposal for reclassification of N staging system in penile cancer patients, based on number of positive lymph nodes. ( 29285831 )
2017
41
Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. ( 29288008 )
2017
42
Analysis of Knowledge Level in Brazilian Students about Human Papillomavirus Infection and Development of Penile Cancer ( 28612588 )
2017
43
Differences in Survival by Receipt of Lymph Node Dissection inA Patients with Invasive Penile Cancer: Results from NCDB. ( 29248557 )
2017
44
Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence Free Survival for Patients with Penile Cancer. ( 28652123 )
2017
45
Racial disparity and survival outcomes between African-American and Caucasian American men with penile cancer. ( 29281853 )
2017
46
E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers. ( 28753861 )
2017
47
Robotic inguinal lymphadenectomy for penile cancer: the why, how, and what. ( 29184779 )
2017
48
Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. ( 27771796 )
2017
49
Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. ( 28666722 )
2017
50
Subclassification of pN3 staging systems for penile cancer: Proposal for modification of the current TNM classification. ( 28578871 )
2017
Sources

Variations for Penile Cancer

About this section

Cosmic variations for Penile Cancer:

9
(show top 50) (show all 1024)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6949578 TP63 skin,penis,carcinoma,NS c.1922C>T p.A641V 3:189894381-189894381 14
2 COSM10648 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
3 COSM748 PIK3CA skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 14
4 COSM35624 MYCN skin,penis,carcinoma,NS c.131C>T p.P44L 2:15942195-15942195 14
5 COSM6949581 DOT1L skin,penis,carcinoma,NS c.4292C>T p.A1431V 19:2226813-2226813 14
6 COSM729830 skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 14
7 COSM6949580 skin,penis,carcinoma,NS c.4292C>T p.A1431V 19:2226813-2226813 14
8 COSM99022 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
9 COSM1640851 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
10 COSM99914 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
11 COSM3355994 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 14
12 COSM99024 skin,penis,carcinoma,NS c.245G>A p.R82H 17:7675088-7675088 14
13 COSM99023 skin,penis,carcinoma,NS c.128G>A p.R43H 17:7675088-7675088 14
14 COSM6949579 skin,penis,carcinoma,NS c.1640C>T p.A547V 3:189894381-189894381 14
15 COSM6932965 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6172C>T p.P2058S 16:72796510-72796510 7
16 COSM6949138 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.10363C>T p.P3455S 16:72787913-72787913 7
17 COSM6963354 ZFHX3 skin,NS,carcinoma,Merkel cell carcinoma c.6661G>A p.E2221K 16:72796021-72796021 7
18 COSM6935975 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.380C>T p.S127F 11:102114202-102114202 7
19 COSM6912621 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.630G>C p.M210I 11:102162513-102162513 7
20 COSM6917521 YAP1 skin,NS,carcinoma,Merkel cell carcinoma c.371G>C p.R124P 11:102114193-102114193 7
21 COSM6932922 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.855+1G>T p.? 6:43777666-43777666 7
22 COSM6947750 VEGFA skin,NS,carcinoma,Merkel cell carcinoma c.983G>A p.G328E 6:43780752-43780752 7
23 COSM6917817 TSHR skin,NS,carcinoma,Merkel cell carcinoma c.1105G>A p.E369K 14:81143163-81143163 7
24 COSM6917819 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.2519C>T p.A840V 16:2074363-2074363 7
25 COSM6505726 TSC2 skin,NS,carcinoma,Merkel cell carcinoma c.5213C>T p.S1738F 16:2088279-2088279 7
26 COSM6927263 TSC1 skin,NS,carcinoma,Merkel cell carcinoma c.2204C>T p.A735V 9:132903655-132903655 7
27 COSM6917821 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1871C>T p.S624F 16:2176173-2176173 7
28 COSM6932958 TRAF7 skin,NS,carcinoma,Merkel cell carcinoma c.1601A>T p.Y534F 16:2175597-2175597 7
29 COSM11166 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.406C>T p.Q136* 17:7675206-7675206 7
30 COSM10863 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.833C>T p.P278L 17:7673787-7673787 7
31 COSM10939 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.832C>T p.P278S 17:7673788-7673788 7
32 COSM45167 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.402T>A p.F134L 17:7675210-7675210 7
33 COSM78687 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.313G>A p.G105S 17:7676056-7676056 7
34 COSM6920904 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.767C>G p.T256R 17:7674196-7674196 7
35 COSM10794 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.796G>A p.G266R 17:7673824-7673824 7
36 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 17:7674221-7674221 7
37 COSM44140 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.596G>T p.G199V 17:7674935-7674935 7
38 COSM11073 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 7
39 COSM10654 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.637C>T p.R213* 17:7674894-7674894 7
40 COSM43681 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.647T>G p.V216G 17:7674884-7674884 7
41 COSM10726 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.856G>A p.E286K 17:7673764-7673764 7
42 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 17:7673802-7673802 7
43 COSM10705 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.586C>T p.R196* 17:7674945-7674945 7
44 COSM11966 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.485T>A p.I162N 17:7675127-7675127 7
45 COSM45114 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 7
46 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 17:7674220-7674220 7
47 COSM11183 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.799C>T p.R267W 17:7673821-7673821 7
48 COSM43753 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 7
49 COSM44135 TP53 skin,scalp,carcinoma,squamous cell carcinoma c.724T>G p.C242G 17:7674239-7674239 7
50 COSM44218 TP53 skin,lower leg,carcinoma,squamous cell carcinoma c.536A>C p.H179P 17:7675076-7675076 7
Sources

Expression for Penile Cancer

About this section
Search GEO for disease gene expression data for Penile Cancer.
Sources

Pathways for Penile Cancer

About this section

Pathways related to Penile Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.81 CCND1 EGFR HRAS IFNA2 TP53
2
Endometrial cancer 37
Show member pathways
 12.69 CCND1 CDKN2A EGFR HRAS TP53
3
Glioma 37
Show member pathways
 12.54 CCND1 CDKN2A EGFR HRAS TP53
4
Gastric cancer 37
Show member pathways
 12.52 CCND1 CDKN2A EGFR HRAS TP53
5
Regulation of IFNA signaling 66
Show member pathways
 12.49 CCND1 EGFR HRAS IFNA2
6
Pathways in cancer 37
12.45 CCND1 CDKN2A EGFR HRAS IFNA2 TP53
7
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.42 CCND1 HRAS IFNA2 TP53
8
Development EGFR signaling pathway 22
Show member pathways
 12.39 CCND1 EGFR HRAS TP53
9
ErbB signaling pathway 1 37
Show member pathways
 12.32 CCND1 EGFR HRAS TP53
10
HTLV-I infection 37
12.27 CCND1 CDKN2A HRAS TP53
11
MicroRNAs in cancer 37
12.2 CCND1 CDKN2A EGFR HRAS TP53
12
Proteoglycans in cancer 37
12.11 CCND1 EGFR HRAS TP53
13
Viral carcinogenesis 37
12.1 CCND1 CDKN2A HRAS TP53
14
Colorectal Cancer Metastasis 64
12.07 CCND1 EGFR TP53
15
Integrated Breast Cancer Pathway 1
12.03 CCND1 EGFR TP53
16
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12 CCND1 EGFR HRAS
17
AKT Signaling Pathway 67
11.99 CCND1 EGFR HRAS TP53
18
FoxO signaling pathway 37
Show member pathways
 11.97 CCND1 EGFR HRAS
19
TGF-beta Signaling Pathway (WikiPathways) 1
11.95 APP CCND1 TP53
20
Cellular senescence (KEGG) 37
11.94 CCND1 CDKN2A HRAS TP53
21
Signaling by PTK6 66
Show member pathways
 11.93 CCND1 EGFR HRAS
22
Development IGF-1 receptor signaling 22
Show member pathways
 11.91 CCND1 HRAS TP53
23
Spinal Cord Injury 1
11.89 CCND1 EGFR TP53
24
Thyroid hormone signaling pathway 37
11.86 CCND1 HRAS TP53
25
Senescence and Autophagy in Cancer 1
11.82 CDKN2A HRAS TP53
26
Hepatitis C 37
11.82 EGFR HRAS IFNA2 TP53
27
Jak-Stat Signaling Pathway 67
11.78 EGFR HRAS IFNA2
28
DNA Damage Response (only ATM dependent) 1
11.73 CCND1 CDKN2A HRAS TP53
29
Central carbon metabolism in cancer 37
11.55 EGFR HRAS TP53
30
Copper homeostasis 1
11.43 APP CCND1 TP53
31
Glioblastoma Multiforme 64
11.4 CCND1 CDKN2A EGFR HRAS TP53
32
Transcription_Transcription factor Tubby signaling pathways 22
11.2 EGFR HRAS TP53
33
a6b1 and a6b4 Integrin signaling 1
11.18 EGFR HRAS
34
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.16 CRP HRAS
35
Extracellular vesicle-mediated signaling in recipient cells 1
11.16 EGFR HRAS
36
Photodynamic therapy-induced AP-1 survival signaling. 1
11.16 CCND1 CDKN2A EGFR TP53
37
EGFR Transactivation by Gastrin 66
Show member pathways
 11.09 EGFR HRAS
38
MNAR-PELP1 and Estrogen Receptor Interaction 64
11.04 CCND1 HRAS
39
Inhibition of Ribosome Biogenesis by p14(ARF) 64
11.01 CDKN2A TP53
40
TP53 Network 1
Show member pathways
 11.01 CDKN2A TP53
41
Bladder cancer 37 1
10.88 CCND1 CDKN2A EGFR HRAS TP53
42
ERK Pathway in Huntingtons Disease 1
10.77 EGFR HRAS
Sources

GO Terms for Penile Cancer

About this section

Biological processes related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.98 APP CDKN2A EGFR HRAS TP53
2 negative regulation of cell proliferation GO:0008285 9.81 APP CDKN2A HRAS TP53
3 apoptotic process GO:0006915 9.8 APP CDKN2A HRAS IFNA2 TP53
4 cell cycle arrest GO:0007050 9.71 CDKN2A HRAS TP53
5 intrinsic apoptotic signaling pathway GO:0097193 9.61 HRAS TP53
6 cell aging GO:0007569 9.6 HRAS TP53
7 cellular response to gamma radiation GO:0071480 9.59 HRAS TP53
8 response to X-ray GO:0010165 9.58 CCND1 TP53
9 positive regulation of G2/M transition of mitotic cell cycle GO:0010971 9.57 APP CCND1
10 cellular senescence GO:0090398 9.56 CDKN2A HRAS
11 regulation of long-term neuronal synaptic plasticity GO:0048169 9.55 APP HRAS
12 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.52 APP EGFR
13 Ras protein signal transduction GO:0007265 9.5 CDKN2A HRAS TP53
14 positive regulation of superoxide anion generation GO:0032930 9.49 CRP EGFR
15 replicative senescence GO:0090399 9.48 CDKN2A TP53
16 mitotic G1 DNA damage checkpoint GO:0031571 9.46 CCND1 TP53
17 positive regulation of protein phosphorylation GO:0001934 9.46 APP CCND1 EGFR HRAS
18 amyloid fibril formation GO:1990000 9.43 APP CDKN2A
19 astrocyte activation GO:0048143 9.37 APP EGFR
20 positive regulation of gene expression GO:0010628 9.35 APP CDKN2A CRP HRAS TP53
21 response to UV-A GO:0070141 9.26 CCND1 EGFR
22 positive regulation of phosphorylation GO:0042327 8.8 APP EGFR IFNA2

Molecular functions related to Penile Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 CCND1 CDKN2A EGFR TP53
2 enzyme binding GO:0019899 8.92 APP CCND1 EGFR TP53
Sources

Sources for Penile Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....